Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules vs Fluconazole and Placebo in Treatment of Acute Vulvovaginal Candidiasis in Subjects With Recurrent Vulvovaginal Candidiasis

NCT03840616 is registered in ClinicalTrials.gov with Mycovia Pharmaceuticals Inc. as lead sponsor.

NCT NCT03840616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03840616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules vs Fluconazole and Placebo in Treatment of Acute Vulvovaginal Candidiasis in Subjects With Recurrent Vulvovaginal Candidiasis
Lead sponsor
Mycovia Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 13, 2019
Completion date
December 2, 2020
Enrollment
219 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent vulvovaginal candidiasis